BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Catena idebenone: Additional Phase II data

Additional data from the double-blind, international Phase II RHODOS trial in 39 evaluable patients who had severely impaired color contrast sensitivity at baseline showed that 900 mg/day Catena significantly improved blue-yellow color contrast from baseline to week 24 vs. placebo (7.3% improvement vs. 6.4% worsening, p=0.008), but non-significantly improved red-green color contrast vs. placebo (p=0.239). Data were presented at the American Neurological Association meeting in...

Read the full 301 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >